CASI Pharmaceuticals, Inc. (CASI) Position Held by California Public Employees Retirement System
California Public Employees Retirement System held its position in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,518 shares of the biotechnology company’s stock at the end of the 2nd quarter. California Public Employees Retirement System owned about 0.23% of CASI Pharmaceuticals worth $143,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of analysts recently weighed in on CASI shares. ValuEngine raised shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 15th. Maxim Group reissued a “buy” rating and issued a $4.00 target price on shares of CASI Pharmaceuticals in a research note on Friday, September 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of CASI Pharmaceuticals in a research note on Friday, September 8th.
In other news, Director Wei-Wu He purchased 100,000 shares of CASI Pharmaceuticals stock in a transaction on Tuesday, October 10th. The shares were purchased at an average cost of $1.95 per share, for a total transaction of $195,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders purchased 996,329 shares of company stock worth $1,647,138. 24.52% of the stock is currently owned by insiders.
CASI Pharmaceuticals (NASDAQ:CASI) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. analysts expect that CASI Pharmaceuticals, Inc. will post -0.15 earnings per share for the current fiscal year.
CASI Pharmaceuticals Profile
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Want to see what other hedge funds are holding CASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CASI Pharmaceuticals, Inc. (NASDAQ:CASI).
Receive News & Stock Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.